To evaluate a practical approach of safely evaluating the performance of BGMS within the required hypoglycaemic range according to the ISO 15197:2013 standards using a modified 1-step hyperinsulinemic hypoglycaemic clamp under controlled and reproducible conditions.
INTRODUCTION

OBJECTIVE
METHODS
19 / 19 patients successfully completed the hypoglycemic glucose clamps to achieve a stable glucose level with no significant adverse events related to hypoglycemia. All patients participated in UP and a subset of 15 also took part in system accuracy as per the requirements from the overall study population enrolment from other sites and the minimum requirements set out in the ISO 15197:2013 standards. 
Glucose Clamp Characteristics & Stability
The total duration of each Glucose clamp was variable and lasted between 1 and 3 hours to allow for a BG stabilization period prior to BGMS system evaluation to be performed. Clamp quality assessed by control deviation and variability (CV) was 1.6 mg/dL (3.94%) during the system evaluation periods (Figures 2 & 3) .
RESULTS
The ISO 15197: 2013 standards clearly identify the performance criteria that BG systems need to fulfil for marketing approval. This creates several challenges for manufacturing companies which often have tight timelines but require reliable and reproducible evaluation of their devices during this development process. Obtaining data in subjects within the hypoglycaemic ranges can be difficult and often requires long periods of time to recruit subjects, test systems and analyse data. Testing within this target range poses several issues to the investigating staff including substantial instability of the blood glucose due to the natural counter regulatory responses to hypoglycaemia and safety concerns if subjects are symptomatic and require treatment. The ISO 15197;2013 only dictates that 8 samples be collected naturally within 50-80mg/L range for system accuracy, however the Sponsor felt it was important as a manufacturer to obtain up to 20 samples for UP and SA sampling to demonstrate performcance at these low glucose levels as good practice. Therefore, utilising a glucose clamp technique to safely induce hypoglycaemia in a controlled and reproducible manner is a distinct advantage. It provides manufacturers and regulators a quantitative reassurance of the stability of the blood glucose during the evaluation of measuring accuracy at this essential target range. It also provides additional safety of the subjects who can be reassured by the close level of monitoring during this undesirable period. We implemented a manual glucose clamping technique that was developed and validated specifically for this type of performance evaluation of BGMS which is of comparable quality to automatic glucose clamping techniques described by Zijlstra et al. 2016.
It may be suggested that by using the glucose clamp approach to evaluate BGMS and fulfil the marketing approval performance criteria the evaluation of BG systems within clinically meaningful ranges can be improved. The Glucose Clamp Technique could help compliance with the ISO 15197: 2013 standard and concerns that have been published by the European Association for the Study of Diabetes (EASD) and the Diabetes Technology Society (DTS) advocating the need for post marketing surveillance programs and development of test protocols to assess BG system performance.
DISCUSSION
This study shows that the glucose clamp approach is successful for the evaluation of BGMS performance under controlled conditions at hypoglycaemic levels. This approach allows for the precision testing of the BGMS whilst glycemia is kept constant. The methodology is safe, reproducible and can be performed over a short period of time.
CONCLUSION
The International Organisation for Standardisation ISO 15197:2015 (replacing 15197:2013 -In vitro diagnostic test systems requirements for blood glucose monitoring systems for self-testing in managing diabetes mellitus) is now widely adopted by manufacturers of blood glucose monitoring systems (BGMSs) to demonstrate conformance to the international standards and to the regulatory authorities.
One of the primary objectives of the standard is to establish requirements that result in acceptable performance of new BGMS. "System accuracy" is the term used to communicate the analytical capability of a blood-glucose monitoring system to the intended users and describes the ability of a glucose monitoring system to produce measurement results that agree with true glucose values when the system is used as intended. "User Performance" is the term used to access the accuracy of the BGMS in the hands of the user. It is not a requirement to test for UP as per ISO 15197;2013, however this assement was performed to generate UP data that would be expected for FDA registration. 
Practical Challenges of
TABLE 1 -ADVANTAGES AND DISADVANTAGES OF GLUCOSE CLAMP APPROACH
ADVANTAGES
-Glucose concentrations within the hypoglycaemic range can be achieved in a controlled manner -Stable blood glucose can be established repeatedly at target concentrations for a which allows a clinical evaluation of a BG system's precision -Accuracy, precision, and trueness can be evaluated at the same time in a single clinical experiment -Recruitment time of subjects is significantly reduced -Timelines for regulatory studies much improved DISADVANTAGES -Glucose clamp studies can be more expensive than recruiting naturally hypoglycemic subjects -Only few specialised research centres available to perform similar testing 
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Glucose Clamp Procedure
After an initial screening visit, eligible subjects were invited to return to the clinical research centre for the glucose clamp procedure. Subjects were admitted to the clinical research centre on the evening prior to study to maintain a controlled environment and consulted with a study physician for any insulin dose adjustments required. Meticulous avoidance of hypoglycaemia was maintained in the week prior to the study by the subjects. A manual clamp technique developed by BKE was implemented on the morning of the study by the medical team. Subjects were connected to independent IV infusions of glucose and insulin via an indwelling cannula. Infusions were controlled by Harvard pumps (Harvard Apparatus, MA, USA). Plasma glucose was measured at intervals of 5 min levels (SensoStar GLH six, DiaSys Diagnostic Systems, Holzheim, DE) until blood glucose (BG) levels were lowered to below 4.2mmol/l (75mg/dl) using a previously validated Hypoglycemic clamping technique at BKE to ensure steady descent into hypoglycaemia (Figure 1 ). BG levels were maintained at the target BG level (within at ±10% range) via a variable-rate infusion of 20% dextrose using algorithms generated by BKE originating from equations described by DeFronzo et al. 
